Similar to the other comorbidities present in the pediatric MetS, the therapeutic market targeting arterial hypertension is constantly developing, the newest products coming into focus being endothelin receptor antagonists (Darusentan) and renin inhibitors (Aliskiren) (106). Here, REN is linked to metabolic syndrome.